- Home
- STFS vs SLGL Comparison
STFS vs SLGL Comparison
Compare STFS & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STFS
- SLGL
- Stock Information
- Founded
- STFS 2015
- SLGL 1997
- Country
- STFS China
- SLGL Israel
- Employees
- STFS N/A
- SLGL N/A
- Industry
- STFS
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- STFS
- SLGL Health Care
- Exchange
- STFS NYSE
- SLGL Nasdaq
- Market Cap
- STFS 16.2M
- SLGL 19.3M
- IPO Year
- STFS 2024
- SLGL 2018
- Fundamental
- Price
- STFS $1.62
- SLGL $8.02
- Analyst Decision
- STFS
- SLGL Buy
- Analyst Count
- STFS 0
- SLGL 1
- Target Price
- STFS N/A
- SLGL $40.00
- AVG Volume (30 Days)
- STFS 639.8K
- SLGL 6.5K
- Earning Date
- STFS 02-14-2025
- SLGL 08-15-2025
- Dividend Yield
- STFS N/A
- SLGL N/A
- EPS Growth
- STFS N/A
- SLGL N/A
- EPS
- STFS 0.01
- SLGL N/A
- Revenue
- STFS $16,754,197.00
- SLGL $12,103,000.00
- Revenue This Year
- STFS N/A
- SLGL N/A
- Revenue Next Year
- STFS N/A
- SLGL $31.17
- P/E Ratio
- STFS $185.32
- SLGL N/A
- Revenue Growth
- STFS 75.86
- SLGL 603.66
- 52 Week Low
- STFS $0.80
- SLGL $3.34
- 52 Week High
- STFS $17.91
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- STFS N/A
- SLGL 58.29
- Support Level
- STFS N/A
- SLGL $7.62
- Resistance Level
- STFS N/A
- SLGL $8.49
- Average True Range (ATR)
- STFS 0.00
- SLGL 0.33
- MACD
- STFS 0.00
- SLGL 0.08
- Stochastic Oscillator
- STFS 0.00
- SLGL 61.88
About STFS STAR FASHION CULTURE HOLDINGS LIMITED
Star Fashion Culture Holdings Ltd is a content marketing solutions services provider. The company offer services focusing on marketing campaign planning and execution, offline advertising services; and online precision marketing services. The services also include marketing campaign planning and execution, events including marathons, sports events, and music festivals.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.